Uncategorized
Twelve startups to showcase at SLAS Europe 2026
SLAS, the Society of Laboratory Automation and Screening, has introduced the 12 companies selected for the Innovation AveNEW programme at SLAS Europe 2026 Conference and Exhibition, taking place 19-21 May in Vienna, Austria.
Innovation AveNEW provides a platform for participants to showcase their new company, product or service within a specially designated area on the exhibition floor, where they can directly engage with purchasing influencers and decision-makers from more than 40 countries.
SLAS covers the cost of exhibition fees, travel and lodging (for one representative) and provides access to business consulting and mentorship, and exclusive promotional opportunities.
Applicants are reviewed by the Innovation AveNEW panel based on technical merit and commercial feasibility, with criteria, inclusive of, but not limited to compelling science and technology, start-up status, strength of management team, clarity of vision and market opportunity, and impact on the field of laboratory automation and technology. Each successful company also has the opportunity to submit for the SLAS Ignite Award, the winner of which will receive €5,000.
The Innovation AveNEW companies for 2026 are:
- 8-BOT Robotics (Germany)
- Chemetrian (USA)
- Culturon Pty (Australia)
- DaltonTx (United Kingdom)
- The Ensynble (USA)
- linkdlab (Germany)
- Lutèce Dynamics (France)
- PartitionBio (United Kingdom)
- Scalables (USA)
- Sync Biosystems (Netherlands)
- Syntopia (France)
- Trince (Belgium)
“SLAS has always prioritised providing life sciences technology start-ups with the invaluable market access, user feedback and business counsel to grow and scale their business. Supporting innovative companies with these critical tools and services is a key part of the SLAS mission, to catalyse multidisciplinary innovation across the sector,” commented Vicki Loise, Chief Executive Officer of SLAS. “We’re honoured to welcome a new cohort of Innovation AveNEW startup companies shaping the future of life sciences discovery and technology to our European conference and exhibition in Vienna.”
The post Twelve startups to showcase at SLAS Europe 2026 appeared first on Drug Discovery World (DDW).
Uncategorized
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
Sanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a “measured risk.” Read More
Uncategorized
STAT+: Gilead to buy cancer biotech Tubulis for more than $3 billion
In a move that will grow its oncology pipeline, Gilead Sciences is spending more than $3 billion to buy the German biotech Tubulis, the companies said Tuesday.
The deal includes an upfront payment of $3.15 billion and up to $1.85 billion more if certain milestones are reached. It also highlights both the therapeutic and commercial promise of antibody-drug conjugates, the next-generation chemotherapy treatments that the privately held Tubulis is developing.
Gilead’s latest move comes just months after it said it would acquire Arcellx in a deal worth $7.8 billion. The two companies had already been working together on a multiple myeloma CAR-T therapy that could be approved later this year. Gilead last month also announced that it was buying Ouro Therapeutics, which is focused on drugs for autoimmune disease, for up to $2.18 billion.
In a move that will grow its oncology pipeline, Gilead Sciences is spending more than $3 billion to buy the German biotech Tubulis, the companies said Tuesday.
The deal includes an upfront payment of $3.15 billion and up to $1.85 billion more if certain milestones are reached. It also highlights both the therapeutic and commercial promise of antibody-drug conjugates, the next-generation chemotherapy treatments that the privately held Tubulis is developing.
Gilead’s latest move comes just months after it said it would acquire Arcellx in a deal worth $7.8 billion. The two companies had already been working together on a multiple myeloma CAR-T therapy that could be approved later this year. Gilead last month also announced that it was buying Ouro Therapeutics, which is focused on drugs for autoimmune disease, for up to $2.18 billion.
In its third acquisition of 2026, Gilead is spending $3.15 billion upfront to snag a next-generation antibody-drug conjugate platform from German startup Tubulis.
The California biopharma could pay out another $1.85 billion down the road …
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
STAT+: Gilead to buy cancer biotech Tubulis for more than $3 billion
Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCs
BioNTech to shutter Singapore HQ after ‘comprehensive review’
Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3
STAT+: Merck’s experimental HIV prevention pill could be made for less than $5 a year, researchers say
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Contributors9 years ago
The final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years ago
According to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years ago
The old and New Edition cast comes together to perform
-
Uncategorized9 years ago
Phillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years ago
Uber and Lyft are finally available in all of New York State
-
Uncategorized9 years ago
Disney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years ago
Steph Curry finally got the contract he deserves from the Warriors